Non-valvular atrial fibrillation (NVAF) is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Unlike valvular atrial fibrillation, which is associated with heart valve issues, NVAF occurs in the absence of significant valve abnormalities. NVAF poses an increased risk of blood clots forming in the atria, which can potentially lead to stroke. Managing NVAF typically involves anticoagulant medications to prevent blood clot formation and control heart rate. Additionally, healthcare providers may explore rhythm control strategies to restore a normal heart rhythm. As NVAF is often a chronic condition, a comprehensive approach that considers individual patient factors is crucial for effective treatment and reducing the risk of associated complications. Regular monitoring and collaboration between patients and healthcare professionals are key components of managing non-valvular atrial fibrillation.
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain